Clinical Trial Update: Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer. [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating pembrolizumab (Keytruda) effects on biomarkers in early breast cancer, including triple-negative and hormone receptor–negative diseas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor Negative Neoplasm
• Triple-negative Breast Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Universitaire Ziekenhuizen KU Leuven | Conditions: Breast Cancer, Triple Negative Breast Cancer | EARLY_Phase 1 | Status: COMPLETED | Results posted: 2021-05-19